What did stage 3 PT-141 research find in women?

What is the clearest answer from the larger tests?

A slight rise in desire doesn't always mean feeling much better overall. The strongest tests asked how much desire women felt and how troubled they were.

Two stage 3 studies examined PT-141; these were the major tests before considering approval. Researchers found small gains, then followed longer use during a 52-week study.

You can see who approval includes: women still having monthly periods. Other research measured brain activity, appetite, and erections, with less settled answers.

Earlier erection tests in men never produced approval for that use. You can read those findings below, including why some results remain disputed.

What changed in erections and animal behavior during early tests?

Men who had difficulty getting firm erections developed erections after PT-141 during early tests ^[1]. The erections appeared quickly and grew stronger when researchers used larger amounts ^[1].

Rats and monkeys also developed erections, and tests showed certain brain cells becoming active. Those animal findings helped researchers locate the drug's action within the brain.

Female rats given PT-141 approached males more, suggesting a change in seeking sex ^[2]. Their back-arching posture, movement during mating, and movement in general didn't change.

The difference mattered because seeking sex and responding physically are separate parts of sexual behavior. Researchers turned toward testing women whose loss of interest troubled them.

One review examined the animal findings about brain activity and female sexual behavior ^[8]. Another asked whether related drugs might help sexual problems in men or women ^[9].

Those reviews explain why the later studies focused on desire rather than every sexual problem. For you, the animal results remain reasons to investigate, rather than a measured human benefit.

What did PT-141 for women change over the study?

The main PT-141 for women studies asked about desire and upset over its loss. Two matching stage 3 studies, the major tests done before considering approval, examined that problem.

Researchers enrolled 1,267 women whose periods hadn't ended and whose low desire caused distress. Treatment was either 1.75 milligrams by shot or a placebo, containing no active medicine ^[3].

After 24 weeks, women receiving the medicine reported slightly more desire than the comparison group ^[3]. Question 13 asked how much the lack of interest in sex bothered each woman.

Distress eased slightly more in women receiving medicine than in those without it. Both studies found these changes, but the gains didn't establish a satisfying sex life.

Another 684 women joined a 52-week follow-up, knowing they were receiving the medicine ^[4]. Desire stayed somewhat higher, without another safety concern emerging during the extra period of treatment.

Sickness affected 40.4% of women, redness and warmth affected 20.6%, and headaches affected 12.0%. A further report examined how women experienced the benefits and these unwanted effects ^[13].

Bremelanotide gained approval in June 2019 for this particular problem ^{[11] [12]}. The women covered hadn't finished their periods and had no other cause explaining the loss.

You can weigh the small desire gain alongside the common sickness. You can't take these women's findings as an established treatment for male erection trouble.

What can PT-141 benefits tell you about a woman’s sex life?

PT-141 benefits concerned whether women wanted sex more and felt less troubled about low desire. Question 13 asked women how upsetting they found their lack of desire.

Over 24 weeks, the drug group reported a small rise in desire compared with women without medicine ^[3]. Their distress eased slightly too, without proving a large improvement in daily life.

In another study, women felt greater desire lasting up to 24 hours after treatment ^[5]. Scans showed changes inside the brain during a task of viewing sexual images.

These tests can't tell you that sex became more satisfying for each woman. You won't find a settled answer about how much those gains mattered to women ^{[3] [5]}.

Why is a small measured gain open to question?

A questionnaire can detect a change that feels too small to matter much. Spielmans reviews from 2021 and 2024 questioned the usefulness of the reported gains ^{[3] [4]}.

The reviews asked whether the women felt enough relief in their daily lives. They also challenged how the benefits were presented to people reading the results.

Both trials met the goals set before treatment began, but the gains remained small ^[3]. You can see that goals were met without knowing whether women felt worthwhile relief.

Another review examined difficulties during development before the medicine gained approval ^[16]. That review considered the modest benefit beside the unwanted effects women experienced ^[16].

Approval identifies a use with supporting evidence, without promising a large improvement. You still need to weigh how much relief occurred beside the discomfort women experienced.

How uncertain is the evidence on PT-141 for men?

Early PT-141 for men tests looked at difficulty getting firm erections ^[1]. Erections appeared quickly, with stronger responses as the amount of medicine increased.

Early experiments also used nose treatment instead of shots to give the medicine. Clearer erection effects appeared above roughly 7 milligrams, an amount used in those experiments.

Stage 2 means earlier testing; those erection results weren't confirmed by the later tests needed for approval ^[11]. Only certain women with lasting, troubling low desire are included in approval.

A man's trouble getting an erection is outside that approved use. Women's desire findings therefore don't settle whether this medicine would help your symptoms.

In 2023, editors raised doubts about Safarinejad and Hosseini's 2008 study of men ^[11]. The study concerned men whose earlier erection treatment hadn't worked.

The cited account doesn't identify that earlier treatment or explain the editors' reason for concern. Without that detail, the findings remain disputed; the warning doesn't establish harm to those men.

Laboratory powder carrying the PT-141 name also lacks official checks of contents, strength, and cleanliness ^[11]. Male use remains under study, with no established erection treatment emerging from this evidence.

Did later research establish more enjoyment or another approved use?

Reviews brought together the small benefits and unwanted effects in women ^[7]. Another review connected desire with activity in particular areas of the brain ^[10].

A review written near approval described the major studies and their 1.75 milligram shots ^[12]. Its account also covered the discomfort that women reported during treatment.

A 2025 study in female Syrian hamsters examined enjoyment rather than the wish for sex ^[14]. Researchers watched whether the animals chose to revisit the place of earlier mating.

Bremelanotide didn't increase that preference, so the test showed no added sign of sexual enjoyment. Researchers watched the animals’ choices rather than asking them to describe pleasure.

That negative result suggests that desire and enjoyment can depend on different brain activity ^[14]. The hamster experiment didn't establish greater pleasure in people receiving the drug.

Women in a study reported an up-to-24-hour rise in desire alongside changed brain activity ^[5]. Scans showed where activity changed, without showing that each sexual experience felt better.

Work involving men and other proposed uses remains early, with some erection findings disputed ^{[1] [11]}. No further use has gained approval alongside the narrow women's use.

For you, the later work mainly explains the action of the drug more closely. More detail about brain cells hasn't established a broader range of reliable treatments.

The clearest result you can find in people remains a small improvement in certain women. Findings about another group or another problem need their own convincing tests.